myelin-basic-protein and Fetal-Hypoxia

This work was conducted in the frames of a multicenter clinical trial. The aim was to study efficacy of cytoflavin (infusion solution) in the prevention and treatment of posthypoxic CNS lesions in premature newborns. The study included 120 premature newborns (gestation period 28-36 weeks) who was born in severe distress and needed the intensive therapy after primary reanimation measures. Cytoflavin was prescribed in the first 2-4 h after the delivery to 61 newborns. The control group included 59 newborns who did not receive the drug. To assess treatment efficacy, the determination of some plasma neurospecific proteins (GFAP, NSE, MBP) was carried out along with standard clinical/instrumental and laboratory monitoring. The results revealed the marked cerebroprotective effect of cytoflavin. The significantly higher rate of normalization of KOC, pO2, PCO2 and elimination of lactate acidosis that led to the reduction of severity and frequency of ischemic and hemorrhagic CNS lesions as well as lower levels of plasma neurospecific proteins were seen in the main group compared to the control one.

Topics: Drug Combinations; Female; Fetal Hypoxia; Flavin Mononucleotide; Glial Fibrillary Acidic Protein; Humans; Hypoxia-Ischemia, Brain; Infant, Newborn; Inosine Diphosphate; Intensive Care Units, Neonatal; Intensive Care, Neonatal; Male; Myelin Basic Protein; Niacinamide; Resuscitation; Succinates; Treatment Outcome